Bio-TechneTECHEarnings & Financial Report
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Revenue
$303.4M
Gross Profit
$204.6M
Operating Profit
$67.0M
Net Profit
$49.1M
Gross Margin
67.4%
Operating Margin
22.1%
Net Margin
16.2%
YoY Growth
3.2%
EPS
$0.31
Bio-Techne Q3 FY2024 Financial Summary
Bio-Techne reported revenue of $303.4M (up 3.2% YoY) for Q3 FY2024, with a net profit of $49.1M (down 30.1% YoY) (16.2% margin). Cost of goods sold was $98.8M, operating expenses totaled $137.6M.
Key Financial Metrics
| Total Revenue | $303.4M |
|---|---|
| Net Profit | $49.1M |
| Gross Margin | 67.4% |
| Operating Margin | 22.1% |
| Report Period | Q3 FY2024 |
Bio-Techne Annual Revenue by Year
Bio-Techne annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.2B |
| 2024 | $1.2B |
Bio-Techne Quarterly Revenue & Net Profit History
Bio-Techne results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $311.4M | -1.5% | $51.0M | 16.4% |
| Q2 FY2026 | $295.9M | -6.4% | $38.0M | 12.8% |
| Q4 FY2025 | $317.0M | +3.5% | $-17.7M | -5.6% |
| Q3 FY2025 | $316.2M | +4.2% | $22.6M | 7.1% |
| Q2 FY2025 | $297.0M | +9.0% | $34.9M | 11.7% |
| Q1 FY2025 | $289.5M | +4.5% | $33.6M | 11.6% |
| Q4 FY2024 | $306.1M | +1.6% | $40.6M | 13.3% |
| Q3 FY2024 | $303.4M | +3.2% | $49.1M | 16.2% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $303.4M | $306.1M | $289.5M | $297.0M | $316.2M | $317.0M | $295.9M | $311.4M |
| YoY Growth | 3.2% | 1.6% | 4.5% | 9.0% | 4.2% | 3.5% | -6.4% | -1.5% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.72B | $2.70B | $2.74B | $2.67B | $2.64B | $2.56B | $2.52B | $2.55B |
| Liabilities | $706.8M | $635.0M | $597.4M | $591.9M | $626.2M | $639.1M | N/A | $465.3M |
| Equity | $2.01B | $2.07B | $2.14B | $2.08B | $2.02B | $1.92B | $2.01B | $2.09B |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $81.0M | $75.5M | $63.9M | $84.3M | $41.1M | $98.2M |